GlassScriptPhysician profile
Anwaar Saeed
NPI 1447490974
$126,381.32
in general payments reported to CMS, 2019-2025
27 companies · $36K in 2025
The $36K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $7,721 · 2021: $13K · 2022: $25K · 2023: $35K · 2024: $9,261 · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $19K · Honoraria: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,200 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,960 · Food and Beverage: $2,133 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,697.50 |
| Travel and Lodging | $18,952.92 |
| Honoraria | $11,220.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,960.00 |
| Food and Beverage | $2,133.15 |
| Education | $185.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $66,480.26 | 2021-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $18,166.92 | 2019-2025 | Imfinzi, Imjudo |
| Beone Medicines USA, INC. | $11,898.33 | 2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $8,962.29 | 2020-2023 | |
| Regeneron Pharmaceuticals, INC. | $4,751.68 | 2025 | Libtayo |
| Daiichi Sankyo INC. | $4,220.00 | 2021 | |
| Array Biopharma INC | $3,780.00 | 2020-2024 | Braftovi |
| Jazz Pharmaceuticals INC. | $2,897.54 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $2,432.29 | 2024 | Opdivo |
| Taiho Oncology, INC. | $2,310.00 | 2023 | |
| Astellas Pharma US INC | $124.03 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $92.55 | 2022 | |
| Gilead Sciences, INC. | $74.09 | 2021-2022 | |
| Glaxosmithkline, LLC. | $67.00 | 2025 | |
| Eisai INC. | $50.00 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $44.65 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $29.69 | 2023-2024 | Onivyde, Somatuline Depot |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwaar Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.